IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. 
Impact of Menstrual Cycle on Antiretroviral Pharmacokinetics in HIV-Infected Women
This study has been withdrawn prior to enrollment.
(Lack of enrollment)
Sponsor:
University of Alabama at Birmingham
Collaborator:
National Institute of Allergy and Infectious Diseases (NIAID)
Information provided by (Responsible Party):
Jennifer King, University of Alabama at Birmingham
ClinicalTrials.gov Identifier:
NCT01394133
First received: July 12, 2011
Last updated: April 29, 2013
Last verified: April 2013
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Data suggests that women taking drugs to treat human immunodeficiency virus (HIV) have higher amounts of drugs in their body compared with men taking the same dose of anti-HIV drugs. The reason for this higher drug exposure has not yet been determined. The primary purpose of this study is to examine whether a pharmacokinetics (factors that determine the amount of drug in the body) of anti-HIV drugs change during different phases of the menstrual cycle in women and ultimately result in higher amounts of drug in the body compared with men. In other words, we plan to examine whether changes in sex hormones throughout the menstrual cycle affect the amount of anti-HIV drugs in HIV infected women. The antiretroviral drugs atazanavir, ritonavir, tenofovir and emtricitabine will be studied.
| Condition | Intervention |
|---|---|
| HIV Infected | Drug: Tenofovir, Emtricitabine, Atazanavir, Ritonavir |
| Study Type: | Observational |
| Study Design: | Observational Model: Cohort Time Perspective: Prospective |
| Official Title: | Impact of Menstrual Cycle on Antiretroviral Pharmacokinetics in HIV-Infected Women |
Resource links provided by NLM:
Further study details as provided by Jennifer King, University of Alabama at Birmingham:
Primary Outcome Measures:
- PK parameters [ Time Frame: 28 days ]The area under the concentration time curve and minimum concentration for tenofovir, emtricitabine, atazanavir and ritonavir
Biospecimen Retention: Samples Without DNA
5 mL of plasma
| Enrollment: | 0 |
| Study Start Date: | July 2011 |
| Study Completion Date: | April 2013 |
| Primary Completion Date: | April 2013 (Final data collection date for primary outcome measure) |
| Groups/Cohorts | Assigned Interventions |
|---|---|
|
HIV+ Female
HIV infected women between 21-40 years of age, not receiving oral contraceptives.
|
Drug: Tenofovir, Emtricitabine, Atazanavir, Ritonavir
Women will be receiving Tenofovir 300mg, Emtricitabine 200mg, Atazanavir 300mg, Ritonavir 100mg, one dose on 2 separate visits. These medications will not be prescribed from the physician and not provided by the study.
|
Eligibility| Ages Eligible for Study: | 21 Years to 40 Years (Adult) |
| Sexes Eligible for Study: | Female |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
Study Population
HIV-infected women will be selected from the primary care office
Criteria
Inclusion Criteria:
- HIV positive females between 21-40 years of age.
- Subjects must be receiving anti-HIV regimen consisting of tenofovir, emtricitabine, atazanavir, and ritonavir for a minimum of 4 weeks prior to the study.
- Subjects must have regular menstrual cycle (period), define at least 10 cycles a year, occurring approximately every 28 days+/- 4 days and cycle length varying by not more than 7 days.
Exclusion Criteria:
- Subjects can not be breast feeding, pregnant, or taking oral contraceptives (birth control pills) for at least 3 months prior to the study.
- Subjects may not have the intrauterine device (IUD), Mirena, in place to prevent pregnancy.
Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01394133
Please refer to this study by its ClinicalTrials.gov identifier: NCT01394133
Locations
| United States, Alabama | |
| University of Alabama at Birmingham | |
| Birmingham, Alabama, United States, 35294 | |
Sponsors and Collaborators
University of Alabama at Birmingham
National Institute of Allergy and Infectious Diseases (NIAID)
More Information
| Responsible Party: | Jennifer King, Assistant Professor, University of Alabama at Birmingham |
| ClinicalTrials.gov Identifier: | NCT01394133 History of Changes |
| Other Study ID Numbers: |
F10102815 1K23AI074390-01A2 ( US NIH Grant/Contract Award Number ) |
| Study First Received: | July 12, 2011 |
| Last Updated: | April 29, 2013 |
Keywords provided by Jennifer King, University of Alabama at Birmingham:
|
HIV Infected Women |
Additional relevant MeSH terms:
|
Ritonavir Atazanavir Sulfate Tenofovir Emtricitabine HIV Protease Inhibitors Protease Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action |
Anti-HIV Agents Anti-Retroviral Agents Antiviral Agents Anti-Infective Agents Cytochrome P-450 CYP3A Inhibitors Cytochrome P-450 Enzyme Inhibitors Reverse Transcriptase Inhibitors Nucleic Acid Synthesis Inhibitors |
ClinicalTrials.gov processed this record on June 28, 2017